Steven Watkins

BCD Bioscience, Inc. is a biotechnology company, which engages in the creation of oligosaccharide library. It also designs a roadmap that connects carbohydrate structures with its functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. The company was founded by Carlito Lebrilla, David Mills, and Bruce German in 2019 and is headquartered in Davis, CA.

Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services.

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.